Home » Regions » Global News » InnoCore Pharmaceuticals, Allergan ink exclusive license agreement

InnoCore Pharmaceuticals, Allergan ink exclusive license agreement

Thursday, October 24, 2013

InnoCore Pharmaceuticals, a privately owned pharma located in the Netherlands, has signed an exclusive license and collaboration agreement with Allergan, a multi-specialty healthcare company headquartered in Irvine, Calif.

The companies will expand their existing collaboration and jointly continue to develop long-acting ocular drug delivery products for the treatment of ophthalmic diseases. Utilizing its patented SynBiosys polymeric drug delivery platform, InnoCore will formulate Allergan’s proprietary drugs into pharmaceutical products expected to be capable of sustained release for many months following a single ocular injection. The SynBiosys drug delivery platform is based on novel biodegradable multi-block co-polymers with unique molecular architectures that allow precise and site-specific delivery of drugs for predetermined periods of time, ranging from weeks to many months.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!